TetraLogic bags lymphoma therapy in $13M buyout

Malvern, PA-based TetraLogic ($TLOG) is buying up Shape Pharmaceuticals and its Phase II-ready lymphoma gel treatment for $13 million in cash. The deal brings TetraLogic a second clinical-stage asset, suberohydroxamic acid phenyl ester (Shape), which is described as a "tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA cutaneous T-Cell lymphoma." The Phase II study is expected to get underway in the fourth quarter of this year. "We are encouraged with Shape's clinical data to date, specifically the response rate and early onset of action, and we expect to advance it into Phase II trials later this year with a goal of evaluating the 6 month efficacy of Shape in Stage IA-IIA CTCL patients," says TetraLogic CEO Kevin Buchi in a statement. Release